Pérdidas de seguimiento de personas con infección por el VIH en la cohorte española VACH en el periodo 2013-2014: importancia de los factores sociodemográficos
Ramón Teira(Hospital Sierrallana), Pepa Muñoz-Sánchez(Hospital de Basurto), Fernando Lozano de León(Hospital Universitario de Valme), Marta Montero, Elisa Martínez(University Hospital and Clinics), Elisabeth Deig(Hospital General de Granollers), Francisco Téllez(Hospital Universitario Puerto Real), Joaquim Peraire(Instituto de Salud Carlos III), Núria Espinosa, Marı́a José Galindo(Hospital Clínico Universitario de Valencia), Francisco González(Universidad de Huelva)
Cited by 14
Related Papers
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
|The Lancet HIV|2021|110